Chat with us, powered by LiveChat

James McKim, Ph.D., DABT

James McKim, Ph.D., DABT

Dr. McKim received his doctorate from Oregon State University in Biochemical and Molecular Toxicology in 1989. He then completed a Post Doctoral Fellowship in the laboratory of Dr. Curtis Klaassen. After completing his Post Doctoral training, he accepted a faculty position at the University of Colorado School of Medicine, in the Pediatric Liver Disease Group. His research was focused on the effects of metal content in zinc-finger transcription factors and the role of that bile acids play in mitochondrial damage.

AIVT-1n1mc-slideshowIn 1994, Dr. McKim accepted a position with Dow Corning as group leader of Biochemical Toxicology. He was awarded the Dow Corning Technical Achievement award for his research on the role of organosiloxanes in liver enzyme induction patterns. In 1998 Dr. McKim became the lead scientist at Pharmacia for the development of in vitro approaches to predict potential adverse effects of new drugs. He was awarded the Preclinical Impact Award for this work and received a US Patent on the method he developed. He was also appointed as a full Scientific Fellow by Pharmacia. In 2003, Dr. McKim Founded CeeTox, Inc a contract research laboratory focused on in vitro methods for predicting toxicity.

In 2014, he founded IONTOX, LLC. Dr. McKim has been a Diplomat of the American Board of Toxicology since 1995. He has been an active full member of the Society of Toxicology since 1980 and has published numerous abstracts, manuscripts, and book chapters. He has three fully issued US Patents and has one pending. He holds the rank of Associate Professor at Western University School of Medicine and is known internationally as a leader in the field of In Vitro Toxicology. He is the Founding Editor and Chief of the Journal “Applied In Vitro Toxicology” Published by Mary Ann Liebert.